Provided by Tiger Trade Technology Pte. Ltd.

Global Partners LP

49.03
+0.30000.62%
Volume:10.47K
Turnover:508.18K
Market Cap:1.67B
PE:23.56
High:49.03
Open:48.59
Low:48.30
Close:48.73
52wk High:59.20
52wk Low:39.58
Shares:34.00M
Float Shares:27.67M
Volume Ratio:0.51
T/O Rate:0.04%
Dividend:2.99
Dividend Rate:6.10%
EPS(TTM):2.08
EPS(LYR):2.41
ROE:13.77%
ROA:3.98%
PB:2.75
PE(LYR):20.34

Loading ...

Embecta: Stable Execution, GLP-1–Driven Growth Optionality, and Attractive Valuation Support Buy Rating and $25 Target

TIPRANKS
·
Feb 06

LifeVantage Earnings Call: GLP-1 Hit Tests Turnaround

TIPRANKS
·
Feb 06

Edible Garden to Participate in ECRM’s Total Wellness: GLP-1, Weight Management, Nutrition & Vitamin Session, February 10–12, 2026

GlobeNewswire
·
Feb 05

Press Release: GLP China Holdings Limited TENDER OFFER TO PURCHASE FOR CASH ANY AND ALL OF ITS U.S.$700,000,000 2.95 PER CENT. NOTES DUE 2026

Dow Jones
·
Feb 05

PepsiCo Charts Growth Amid GLP-1, Ad Headwinds

TIPRANKS
·
Feb 04

Is It Time To Reassess Global Partners (GLP) After Big Five Year Share Gains?

Simply Wall St.
·
Jan 31

Press Release: Global Partners Declares Fourth-Quarter 2025 Cash Distribution of $0.7600 on Common Units

Dow Jones
·
Jan 30

Fractyl Health Advances Revita for Post-GLP-1 Weight Maintenance

TIPRANKS
·
Jan 29

Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

GlobeNewswire
·
Jan 28

Huadong Medicine: HDM1002, as a differentiated oral GLP-1 targeted drug, is positioned to meet unmet and differentiated clinical needs in the global market

Deep News
·
Jan 27

Roche Reports Positive Phase II Trial Results for GLP-1/GIP Dual Receptor Drug

Deep News
·
Jan 27

ASCLETIS-B (01672) Announces Completion of First Dosing in 13-Week US Phase II Study of Oral Small-Molecule GLP-1R Agonist ASC30 for Diabetes

Stock News
·
Jan 26

Ascletis Starts U.S. Phase II Diabetes Trial of Oral GLP-1 Drug ASC30 After Strong Obesity Data

TIPRANKS
·
Jan 26

ASCLETIS-B (01672) Selects Next-Generation Monthly Subcutaneous GLP-1R/GIPR/GCGR Triple Agonist Peptide ASC37 for Clinical Development

Stock News
·
Jan 20

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

prnewswire
·
Jan 20

PolyPeptide lifts revenue and margins in 2025 as GLP-1 demand powers growth

TIPRANKS
·
Jan 19

Net Profit Expected to Surge Over 200%, Sheng Nuo Biotec Feasts on GLP-1 Weight-Loss Market Boom

Deep News
·
Jan 16

Hybio Pharmaceutical Sells GLP-1 Raw Materials for Slimming Products

MT Newswires Live
·
Jan 16

Why GLP-1 users are ditching injections and turning to other weight-loss methods

Dow Jones
·
Jan 16

Embracing Challenges for the Right Cause: WUXI APPTEC (02359) Supports 24 GLP-1 Drugs to Meet Urgent Clinical Needs

Stock News
·
Jan 15